chloroquine has been researched along with norfloxacin in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.09) | 18.7374 |
| 1990's | 3 (13.64) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Batchu, H; Batra, S; Mishra, A; Shukla, PK; Singh, P; Srivastava, K | 1 |
| Kalaria, PN; Raval, DK; Satasia, SP | 1 |
| Karad, SC; Purohit, VB; Raval, DK | 1 |
| Karad, SC; Purohit, VB; Raval, DK; Thakkar, VR; Thakor, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Sankar, C; Umamatheswari, S | 1 |
| Doshi, H; Ray, A; Thakkar, SS; Thakor, P | 1 |
| Doshi, H; Ray, A; Thakkar, SS; Thakkar, VR; Thakor, P | 1 |
| Chu, XM; Gong, KK; Liang, LL; Liu, W; Sun, KL; Wang, C; Zhao, CY | 1 |
| Daraji, DG; Jayanthi, S; Patel, HD; Pithawala, EA; Rajani, DP; Rajani, SD | 1 |
| Hitchman, D; McClean, KL; Shafran, SD | 1 |
| Pedrini, AM; Tornaletti, S | 1 |
| Bia, FJ; Divo, AA; Patton, CL; Sartorelli, AC | 1 |
| Biswas, S; Sharma, AK; Tripathi, KD; Valecha, N | 1 |
| Kulpati, DD; Sharma, AK; Tripathi, KD; Valecha, N | 1 |
| Auparakkitanon, S; Chavalitshewinkoon-Petmitr, P; Pongvilairat, G; Wilairat, P | 1 |
| Daries, W; Fusai, T; Kunesch, G; Le Bras, J; Mosnier, J; Parzy, D; Pradines, B; Ramiandrasoa, F; Rogier, C; Rolain, JM | 1 |
| Ono, C; Tanaka, M | 1 |
2 review(s) available for chloroquine and norfloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Quinoline and quinolone dimers and their biological activities: An overview.
Topics: Anti-Bacterial Agents; Antimalarials; Antineoplastic Agents; Bacteria; Dimerization; Humans; Neoplasms; Quinolines; Quinolones | 2019 |
1 trial(s) available for chloroquine and norfloxacin
| Article | Year |
|---|---|
Norfloxacin is inferior to chloroquine for falciparum malaria in northwestern Zambia: a comparative clinical trial.
Topics: Adult; Chloroquine; Drug Resistance; Female; Follow-Up Studies; Humans; Malaria, Falciparum; Male; Norfloxacin; Prospective Studies; Treatment Outcome; Zambia | 1992 |
19 other study(ies) available for chloroquine and norfloxacin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis and evaluation of new diaryl ether and quinoline hybrids as potential antiplasmodial and antimicrobial agents.
Topics: Anti-Bacterial Agents; Antifungal Agents; Antimalarials; Bacteria; Dose-Response Relationship, Drug; Ethers; Fungi; Microbial Sensitivity Tests; Molecular Structure; Parasitic Sensitivity Tests; Plasmodium falciparum; Quinolines; Structure-Activity Relationship | 2014 |
Synthesis, characterization and pharmacological screening of some novel 5-imidazopyrazole incorporated polyhydroquinoline derivatives.
Topics: Anti-Bacterial Agents; Antifungal Agents; Antimalarials; Bacteria; Dose-Response Relationship, Drug; Fungi; Microbial Sensitivity Tests; Molecular Structure; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymers; Pyrazoles; Quinolines; Structure-Activity Relationship | 2014 |
Design, synthesis and characterization of fluoro substituted novel pyrazolylpyrazolines scaffold and their pharmacological screening.
Topics: Anti-Bacterial Agents; Antifungal Agents; Antimalarials; Bacteria; Dose-Response Relationship, Drug; Drug Design; Fungi; Microbial Sensitivity Tests; Molecular Structure; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyrazoles; Structure-Activity Relationship | 2014 |
Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
Topics: Anti-Infective Agents; Antimalarials; Antitubercular Agents; Bacteria; Bacterial Infections; Fungi; Humans; Malaria, Falciparum; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Mycoses; Plasmodium falciparum; Pyrazoles; Quinolines; Structure-Activity Relationship; Tuberculosis | 2016 |
Synthesis, identification and in vitro biological evaluation of some novel quinoline incorporated 1,3-thiazinan-4-one derivatives.
Topics: Anti-Bacterial Agents; Antimalarials; Antitubercular Agents; Clostridium tetani; Gram-Negative Bacteria; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Plasmodium falciparum; Quinolines; Spectroscopy, Fourier Transform Infrared; Structure-Activity Relationship; Thiazines | 2017 |
1,2,4-Triazole and 1,3,4-oxadiazole analogues: Synthesis, MO studies, in silico molecular docking studies, antimalarial as DHFR inhibitor and antimicrobial activities.
Topics: Anti-Infective Agents; Antimalarials; Folic Acid Antagonists; Molecular Docking Simulation; Oxadiazoles; Spectrum Analysis; Triazoles | 2017 |
Benzothiazole analogues: Synthesis, characterization, MO calculations with PM6 and DFT, in silico studies and in vitro antimalarial as DHFR inhibitors and antimicrobial activities.
Topics: Anti-Bacterial Agents; Antifungal Agents; Antimalarials; Benzothiazoles; Cell Survival; Computer Simulation; Dose-Response Relationship, Drug; Folic Acid Antagonists; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Molecular Structure; Plasmodium falciparum; Quantum Theory; Schizosaccharomyces; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase | 2017 |
Structure based design, synthesis, and biological evaluation of imidazole derivatives targeting dihydropteroate synthase enzyme.
Topics: Anti-Bacterial Agents; Dihydropteroate Synthase; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Imidazoles; Ligands; Microbial Sensitivity Tests; Molecular Structure; Staphylococcus aureus; Structure-Activity Relationship; Vancomycin-Resistant Enterococci | 2021 |
Studies on the interaction of 4-quinolones with DNA by DNA unwinding experiments.
Topics: Chloroquine; DNA, Circular; DNA, Superhelical; Nalidixic Acid; Norfloxacin; Nucleic Acid Conformation; Topoisomerase II Inhibitors | 1988 |
Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro.
Topics: Aminocoumarins; Animals; Anti-Infective Agents; Chloroquine; Ciprofloxacin; Coumarins; Drug Interactions; Drug Resistance; Enoxacin; Fluoroquinolones; Nalidixic Acid; Norfloxacin; Novobiocin; Ofloxacin; Oxolinic Acid; Pefloxacin; Plasmodium falciparum; Tetracycline; Topoisomerase II Inhibitors | 1988 |
In vitro activity of fluoroquinolones against chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum.
Topics: Animals; Chloroquine; Ciprofloxacin; Drug Resistance, Microbial; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Plasmodium falciparum | 1993 |
Curative efficacy of norfloxacin in falciparum malaria.
Topics: Adolescent; Adult; Chloroquine; Drug Administration Schedule; Female; Humans; Malaria, Falciparum; Male; Middle Aged; Norfloxacin; Recurrence | 1993 |
Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro.
Topics: Amsacrine; Animals; Antimalarials; Chloroquine; Drug Resistance, Multiple; Enzyme Inhibitors; Etoposide; Humans; Inhibitory Concentration 50; Malaria, Falciparum; Mefloquine; Naphthyridines; Norfloxacin; Nucleic Acid Synthesis Inhibitors; Plasmodium falciparum; Primaquine; Proguanil; Pyrimethamine; Thailand; Topoisomerase II Inhibitors; Triazines | 2000 |
In vitro potentiation of antibiotic activities by a catecholate iron chelator against chloroquine-resistant Plasmodium falciparum.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Drug Synergism; Iron Chelating Agents; Macrolides; Norfloxacin; Parasitic Sensitivity Tests; Plasmodium falciparum; Spermidine; Tetracycline | 2002 |
Binding characteristics of fluoroquinolones to synthetic levodopa melanin.
Topics: Binding Sites; Chloroquine; Ciprofloxacin; Drug Interactions; Enoxacin; Fluoroquinolones; Levodopa; Levofloxacin; Melanins; Monophenol Monooxygenase; Norfloxacin; Ofloxacin; Quinolones; Timolol | 2003 |